BANU K ARUN to Dose-Response Relationship, Drug
This is a "connection" page, showing publications BANU K ARUN has written about Dose-Response Relationship, Drug.
Connection Strength
0.174
-
Dose-dense chemotherapy for breast cancer. Breast J. 2012 May-Jun; 18(3):261-6.
Score: 0.057
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.055
-
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 11 01; 36(31):3134-3143.
Score: 0.022
-
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54.
Score: 0.014
-
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006 Sep 15; 107(6):1348-54.
Score: 0.010
-
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4274-82.
Score: 0.009
-
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 01; 21(17):3249-54.
Score: 0.008